Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

Date publication

mai 2020

Journal

Clinical lung cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Leprieur EG, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32605892

Résumé

Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national study explored the efficacy of anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) rechallenge in advanced NSCLC patients, looking for potential clinical features associated with greater outcomes.

Mots clés

Efficacy, Immune checkpoint inhibitors, NSCLC, Re-challenge, Selection criteria

Référence

Clin Lung Cancer. 2020 May 8;: